细胞因子诱导的杀伤细胞联合TC方案治疗晚期卵巢癌的疗效及对生活质量和免疫功能的影响

发布时间：2018-04-18 22:00

本文选题：细胞因子诱导的杀伤细胞 + 多西他赛+卡铂　；参考：《中国老年学杂志》2015年17期

【摘要】：目的探讨细胞因子诱导的杀伤细胞(CIK)联合多西他赛+卡铂(TC)方案治疗晚期卵巢癌的疗效及对生活质量和免疫功能的影响。方法选取2012年5月到2014年5月该院收治的晚期卵巢癌患者120例,按照随机数字表法分为观察组和对照组,每组60例,观察组给予CIK联合TC方案治疗,对照组给予TC方案治疗,随访患者2年,比较两组近期疗效、生存率、免疫功能改善、生活质量以及不良反应。结果观察组完全缓解率和总有效率分别为48.3%、86.7%,对照组完全缓解率和总有效率分别为43.3%、78.3%,两组比较无统计学差异(P0.05);观察组治疗后CD3+、CD4+、CD16+CD56+和CD4+/CD8+显著升高,与治疗前及对照组治疗后比较有统计学意义(P0.05),CD8+与治疗前及对照组治疗后比较无统计学意义(P0.05);对照组治疗前后无统计学差异(P0.05);观察组生活质量改善率为76.7%(46/60)显著高于对照组43.3%(26/60)(P0.05);观察组1年和2年生存率分别为81.7%(49/60)、61.7%(37/60),显著高于对照组的61.7%(37/60)、41.7%(25/60)(P0.05);两组不良反应比较无统计学差异(P0.05)。结论 CIK联合TC方案治疗晚期卵巢癌能改善患者的生活质量,提高机体免疫能力,延长患者生存率。
[Abstract]:Objective to investigate the effect of cytokine induced cytotoxicity (CIK) combined with docetabine (TCK) regimen in the treatment of advanced ovarian cancer and its effects on quality of life (QOL) and immune function.Methods from May 2012 to May 2014, 120 patients with advanced ovarian cancer were randomly divided into two groups (60 cases in each group). The observation group was treated with CIK combined with TC regimen, and the control group was treated with TC regimen.Patients were followed up for 2 years to compare the short-term curative effect, survival rate, immune function improvement, quality of life and adverse reaction.Results the complete remission rate and total effective rate of the observation group were 48.3% and 86.7%, respectively, while the complete remission rate and the total effective rate of the control group were 43.3% and 78.3%, respectively. There was no significant difference between the two groups (P 0.05).There was no significant difference in P0.05 / CD8 between before and after treatment in the control group, there was no significant difference between the control group and the control group before and after treatment, and the improvement rate of the quality of life in the observation group was 76. 7% 46 / 60) significantly higher than that in the control group before and after treatment.The 1-year and 2-year survival rates of the control group (43.3%) were 81.779 / 60 / 61.737 / 60, significantly higher than that of the control group (61.737 / 60 / 41.7 / 2560 / P 0.05). There was no significant difference in adverse reactions between the two groups (P0.05).Conclusion CIK combined with TC regimen can improve the quality of life, improve the immune ability and prolong the survival rate of patients with advanced ovarian cancer.
【作者单位】：青海大学附属医院肿瘤妇科;
【分类号】：R737.31

【参考文献】